Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of hypertension
Economic impact of diagnostic testing
12 evidence topics · 11 sources
Screening for primary aldosteronism with aldosterone and renin: Endocrine Society guideline
“We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The GDP used the GRADE Evidence to Decision (EtD) framework to consider contextual factors, such as stakeholder values and preferences, costs and required resources, cost-effectiveness, acceptability, feasibility, and the potential impact on health equity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost and testing burden of broader primary aldosteronism screening: 2025 AHA/ACC guideline
Primary aldosteronism testing rates and treatment in 269 010 Veterans with apparent treatment-resistant hypertension
“Veterans with apparent treatment-resistant hypertension (n = 269 010) from 2000 to 2017” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“4277 (1.6%) patients who were tested for primary aldosteronism were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Testing for primary aldosteronism in patients with apparent treatment-resistant hypertension is cost-effective and may substantially improve long-term outcomes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Underdiagnosis, downstream costs, and cost-effectiveness of broader screening: review
“Fewer than 2% of eligible patients are screened for primary aldosteronism (PA) despite evidence that early detection and targeted therapy are associated with lower cardiovascular and kidney morbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The resulting underdiagnosis not only prolongs exposure to excess aldosterone but also increases healthcare utilization and costs through preventable hospitalizations, procedural interventions, and long-term management of aldosterone-mediated end-organ damage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a modeling study focused on patients with apparent treatment resistant hypertension in the U.S., Gaziano et al. assessed the cost-effectiveness of multiple diagnostic strategies and an empiric MRA treatment approach. Screening with ARR followed by confirmatory testing, AVS, and surgical adrenalectomy, when appropriate, were cost-effective, with incremental cost-effectiveness ratios well within commonly accepted thresholds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of primary aldosteronism screening and subtype diagnosis in resistant hypertension: US decision model
“At a U.S. WTP threshold of $150,000/QALY and without adjustments in HRQoL for patients with surgically untreated PA, CT/AVS strategy is the cost-effective choice with an ICER of $82,000/QALY” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ICERs for CT alone and AVS alone were $200,000/QALY and $492,000/QALY; the other strategies were more costly and less effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Integrating differential patient-reported health-related quality of life adjustments for patients with PA, ICERs for screening patients with CT followed by AVS, CT alone, and AVS alone were $52,000/QALY, $114,000/QALY, and $269,000/QALY gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CT scanning followed by AVS was a cost-effective strategy to screen for PA among patients with resistant hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Test or procedure (CPT or DRG codes as printed) | Base-case cost |
|---|---|
| Screening aldosterone to renin ratio (CPT 82088, 84244, 84132) | “$93”View highlighted excerpt for this quote |
| Confirmatory saline infusion testing (CPT 96365, 93666) | “$141”View highlighted excerpt for this quote |
| Abdominal CT (CPT 74170) | “$329”View highlighted excerpt for this quote |
| Adrenal venous sampling (CPT 75893, 36500) | “$2,645”View highlighted excerpt for this quote |
| Adrenalectomy, surgery and anesthesia (CPT 60650, 00866) | “$3,054”View highlighted excerpt for this quote |
| One year cost of spironolactone | “$158”View highlighted excerpt for this quote |
Medicare fee schedule costs of primary aldosteronism work-up and therapeutic drug monitoring-guided screening in resistant hypertension
“Cost of therapeutic drug monitoring for three drugs=3×$25=$75” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost of screening for primary aldosteronism (PA)=$30 for plasma renin activity+$56 for serum aldosterone=$86” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost of adrenal vein sampling=$2328.73” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost of computed tomographic scan of adrenal glands=$588.53” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A retrospective analysis from a hypertension referral clinic showed that prevalence of PA in adherent patients with TRH by TDM was significantly higher than in nonadherent patients (28% vs 8%, P<.05). Furthermore, cost analysis showed that TDM‐guided PA screening was $590.69 less expensive per patient, with minimal impact on the diagnostic accuracy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of primary aldosteronism screening in all adults with hypertension from age 40: Australian Markov model
“A Markov model was used to estimate the cost-effectiveness of screening for primary aldosteronism in treatment and disease (cardiovascular disease and stroke) naive hypertensive patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The results from this study demonstrated that screening all hypertensive patients for primary aldosteronism from age 40 is cost-effective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care-pathway cost of investigating secondary and apparent treatment-resistant hypertension in a specialist clinic: Ireland
“Sixty-five patients originally recruited for a study of medication adherence in hypertension were included in the sample.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The total care-pathway cost per patient, taking into account clinic visits, clinical reviews, investigations and MDT discussion, was estimated to be €3277, on average. For the patient subgroups, the average cost was €5644 for patients diagnosed with primary aldosteronism and €1446 for patients diagnosed with essential hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare coverage of ambulatory blood pressure monitoring
Cost-effectiveness of clinic, home, and ambulatory blood pressure measurement for diagnosis: US model
“We compared quality-adjusted life-years and lifetime costs ($US 2017 from the US healthcare perspective) associated with clinic BP measurement, home BP monitoring, and ABPM under 2 scenarios: positive and negative initial screen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the screen-positive scenario, ABPM was the dominant strategy among all age and sex groups. Compared with clinic BP measurement, ABPM was associated with cost-savings ranging from $77 (women 80 years of age) to $5013 (women 21 years of age).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ABPM is recommended as the diagnostic strategy of choice for most adults in primary care settings regardless of initial screening results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Practicality and availability of home and ambulatory blood pressure monitoring: 2025 AHA/ACC guideline
Costs and cost-effectiveness of self-measured blood pressure monitoring: Community Guide systematic review of 22 studies
“The literature search from database inception to March 2015 identified 22 studies for inclusion with three types of interventions: SMBP used alone, SMBP with additional support, and SMBP within team-based care (TBC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median costs of intervention were $60 and $174 per person for SMBP alone and SMBP with additional support, respectively, and $732 per person per year for SMBP within TBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SMBP monitoring interventions with additional support or within TBC are cost effective. Cost effectiveness of SMBP used alone could not be determined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote